In a preclinical study, TRAIL/Apo2L selectively induced apoptosis in human MM cells, including cells that were sensitive or resistant to dexamethasone and doxorubicin [78], and reversed the bortezomib-induced upregulation of β-catenin, MCL1, and FLIP, thereby enhancing the cytotoxicity of combination therapy [242]. Here, TNFSF10 is linked to Miyoshi myopathy.